This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, L. W. Articles by Mackey, J. R. Search for Related Content PubMed PubMed Citation Articles by Jones, L. W. Articles by Mackey, J. R.

Effects of Exercise Training on Antitumor Efficacy of Doxorubicin in MDA-MB-231 Breast Cancer Xenografts

Authors' Affiliations: ¹ Department of Medicine, Duke University Medical Center, Durham, North Carolina; ² Faculty of Physical Education; ³ Departments of Pathology; and ⁴ Oncology, University of Alberta, Edmonton, Alberta, Canada

Requests for reprints: Lee W. Jones, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Box 2949, Durham, NC 27705. Phone: 919-668-6791; Fax: 919-681-4785; E-mail: lee.w.jones{at}duke.edu.

Purpose: Exercise is becoming readily accepted as a beneficial adjunct therapy to maintain or enhance quality of life in breast cancer patients undergoing adjuvant chemotherapy. An essential precursor to these studies is to investigate whether exercise modulates the antitumor efficacy of chemotherapeutic agents.

Experimental Design: Athymic female mice were transplanted with MDA-MB-231 breast xenografts and randomly assigned to one of four groups (n = 21 per group): (a) control, (b) exercise-only, (c) doxorubicin-only, or (d) exercise + doxorubicin. Exercise groups performed progressive treadmill running up to 18 m/min at 0% grade for 45 minutes, 5 d/wk for 8 weeks.

Results: Tumor growth delay was significantly longer in the doxorubicin-only and exercise + doxorubicin groups compared with the control (median 42 versus 25 days, P = 0.0082; 36 versus 25 days, P = 0.029, respectively) and exercise-only groups (median 42 versus 25 days, P = 0.029; 36 versus 25 days, P = 0.080, respectively). There was no significant difference between the doxorubicin-only and exercise + doxorubicin groups (median 42 versus 36 days, P = 0.33), suggesting that moderate intensity exercise does not significantly influence doxorubicin-induced tumor growth delay.

Conclusion: These studies are essential to fully understand the safety and application of exercise as a supportive intervention in cancer control.

This article has been cited by other articles:

				C. Doyle, L. H. Kushi, T. Byers, K. S. Courneya, W. Demark-Wahnefried, B. Grant, A. McTiernan, C. L. Rock, C. Thompson, T. Gansler, et al. Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices CA Cancer J Clin, November 1, 2006; 56(6): 323 - 353. [Abstract] [Full Text] [PDF]

				D. E.R. Warburton, C. W. Nicol, and S. S.D. Bredin Health benefits of physical activity: the evidence. Can. Med. Assoc. J., March 14, 2006; 174(6): 801 - 809. [Abstract] [Full Text] [PDF]